AVI BioPharma Strengthens Patent Position in Exon Skipping AVI BioPharma, Inc., a developer of RNA–based drugs, announced the signing of an exclusive worldwide license agreement with the University of Western Australia (UWA) to a patent application related to the treatment of Duchenne Muscular Dystrophy (DMD). [more...]